Search - tctmd.com

Displaying 221 - 240 of 900

Sort: Relevancy | Date

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

News Conference News AHA 2021

No Mortality Difference Between PCI and CABG for Left Main CAD: Meta-analysis

Michael O'Riordan

November 15, 2021

External Support for Vein Grafts in CABG Doesn’t Help Patency: VEST

News Conference News AHA 2021

External Support for Vein Grafts in CABG Doesn’t Help Patency: VEST

Yael L. Maxwell

November 14, 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

News Conference News AHA 2021

Pharmacist-Led Intervention Slashes LDL and BP in 10,000 Patients

Michael O'Riordan

November 13, 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

News Conference News AHA 2021

RAPID CABG: No Penalty to Early Surgery for ACS After Stopping Ticagrelor

Yael L. Maxwell

November 13, 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

News Conference News TCT 2021

SURTAVI: Self-Expanding TAVI Valve Holds Up vs SAVR Through 5 Years

November 05, 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

News Conference News TCT 2021

Myocarditis After COVID-19 Vaccine: Data ‘Reassure’ More and More

November 04, 2021

Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults

News Daily News

Zero CAC Questionable for Ruling Out Obstructive CAD in Young Adults

Michael O'Riordan

November 02, 2021

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

News Daily News

New Chest Pain Guidelines Out at Last: Most Tests Have a Role

Michael O'Riordan

October 28, 2021

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

October 20, 2021

Higher CV Mortality Among More Socially Vulnerable US Adults

News Daily News

Higher CV Mortality Among More Socially Vulnerable US Adults

Yael L. Maxwell

October 20, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

News Features

Four Pillars, Fast? Rapid Sequencing of HF Drugs Faces an Uphill Battle

October 08, 2021

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

News Daily News

Post-ACS Patients With Low LDL Levels Remain at Risk: IMPROVE-IT

Michael O'Riordan

October 04, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

News Daily News

Valve-in-Valve TAVI Bests Redo SAVR in Short Term

Michael O'Riordan

September 20, 2021

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

News Daily News

Big Impact Anticipated With HFpEF Expansion of Sacubitril/Valsartan Label

September 20, 2021

For Young Adults, Cannabis Tied to Doubling of MI Risk

News Daily News

For Young Adults, Cannabis Tied to Doubling of MI Risk

September 08, 2021

From Excess Amputations to Postpregnancy HF, Studies Shine Light on Racial Divide

News Daily News

From Excess Amputations to Postpregnancy HF, Studies Shine Light on Racial Divide

September 06, 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

News Conference News ESC 2021

No Attenuation in CVD Risk Reduction for Patients Treated to Very Low LDLs: FOURIER

Michael O'Riordan

September 02, 2021

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

News Daily News

Therapeutic-Dose Heparin in COVID-19: Who Benefits, Who Doesn’t

August 04, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.